Development and evaluation of two subunit vaccine candidates containing antigens of hepatitis E virus, rotavirus, and astrovirus

Simple item page
dc.contributor.authorXia, Mingen
dc.contributor.authorWei, Chaoen
dc.contributor.authorWang, Leyien
dc.contributor.authorCao, Dianjunen
dc.contributor.authorMeng, Xiang-Jinen
dc.contributor.authorJiang, Xien
dc.contributor.authorTan, Mingen
dc.date.accessioned2019-01-23T14:27:29Zen
dc.date.available2019-01-23T14:27:29Zen
dc.date.issued2016-05-19en
dc.description.abstractHepatitis E virus (HEV), rotavirus (RV), and astrovirus (AstV) are important pathogens that transmit through a common fecal-oral route, causing hepatitis (HEV) and gastroenteritis (RV and AstV) respectively in humans. In this study, we developed and evaluated two subunit vaccine candidates that consisted of the same protruding or spike protein antigens of the three viruses in two formats, a fusion of the three antigens into one molecule (fused vaccine) vs. a mixture of the three free antigens together (mixed vaccine). Both vaccines were easily made via E. coli expression system. Mouse immunization experiments showed that the fused vaccine elicited significantly higher antibody responses against the three viral antigens than those induced by the mixed vaccine. In addition, the mouse post-immune antisera of the fused vaccine revealed significantly higher neutralizing titers against HEV infection in cell culture, as well as significantly higher 50% blocking titers (BT50) against RV VP8-HBGA receptor interactions than those of the post-immune antisera after immunization of the mixed vaccine. Thus, the fused vaccine is a promising trivalent vaccine candidate against HEV, RV, and AstV, which is worth for further development.en
dc.description.notesThe research described in this article was supported by the National Institute of Health, the National Institute of Allergy and Infectious Diseases (5R01 AI089634-01 to X.J. and R21 AI092434-01A1 to M.T.) and an institutional Innovation Fund of Cincinnati Children's Hospital Medical Center to M.T.en
dc.description.sponsorshipNational Institute of Health; National Institute of Allergy and Infectious Diseases [5R01 AI089634-01, R21 AI092434-01A1]; institutional Innovation Fund of Cincinnati Children's Hospital Medical Centeren
dc.format.extent12en
dc.format.mimetypeapplication/pdfen
dc.identifier.doihttps://doi.org/10.1038/srep25735en
dc.identifier.issn2045-2322en
dc.identifier.other25735en
dc.identifier.pmid27194006en
dc.identifier.urihttp://hdl.handle.net/10919/86849en
dc.identifier.volume6en
dc.language.isoenen
dc.publisherSpringer Natureen
dc.rightsCreative Commons Attribution 4.0 Internationalen
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/en
dc.subjectblood group antigensen
dc.subjectcapsid protein formsen
dc.subjectintussusception risken
dc.subjectunited-statesen
dc.subjectp-domainen
dc.subjectnorovirusen
dc.subjectparticleen
dc.subjectneutralizationen
dc.subjectreceptorsen
dc.subjectmortalityen
dc.titleDevelopment and evaluation of two subunit vaccine candidates containing antigens of hepatitis E virus, rotavirus, and astrovirusen
dc.title.serialScientific Reportsen
dc.typeArticle - Refereeden
dc.type.dcmitypeTexten

Files

Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
srep25735.pdf
Size:
1.32 MB
Format:
Adobe Portable Document Format
Description:
Download

Collections

Scholarly Works, Biomedical Sciences and Pathobiology